Schott delivers glass vials for Covid-19 vaccine doses

Indian JV Schott Kaisha leads the supply of vials from India

186
Schott delivers pharma vials to package 2 billion doses of Covid-19 vaccines
Glass vials as packaging for a potential Covid-19 vaccine. Photo - Getty Images (Schott via internet)

German glass manufacturing giant Schott is supporting the world’s fight against Covid-19 with vials capable of holding up to 2 billion vaccination doses. The pharma glass and packaging specialist has reached agreements with leading pharmaceutical companies, including key players in India. The global agreements became effective last month, and first vials are already being delivered to companies in Asia, North America, and Europe.

In India, Schott’s 50-50 joint venture, Schott Kaisha, supplies vials for Covid-19 vaccines to Serum Institute India and several other players. The joint venture operates four manufacturing facilities in the country in Jambusar and Umarsadi in Gujarat, Daman, and Baddi in Himachal Pradesh. The company also produces the pharmaceutical glass tubing for the packaging itself at its global sites, including one in Jambusar in Gujarat.

The specialty glass pioneer is ideally positioned to meet the challenging demand situation since it had started an investment program into its pharma business of US $ 1 billion in 2019 already. In India, this includes a three-digit million-euro number for new Borosilicate glass melting tanks, and for its packaging operations an entirely new production site as well as new modules and lines.

All of Schott’s 20 production sites for pharma glass and packaging are validated by regulatory bodies and pharma companies. This means that additional capacities can be used immediately without further regulatory efforts. Even before the expansions, Schott already produced more than 11 billion pharma containers globally for life-saving drugs per annum, of which a nine-digit figure is manufactured locally in India.

“Schott Kaisha has been known to scale up extremely fast in order to meet customer demands over the past decade, which is also evident from its two new facilities in Umarsadi and Baddi. Thanks to our strong supply chain and support from Schott’s global sites, we are in a very strong position to meet our customer’s current and anticipated requirements. We are confident that we can quickly expand our production capabilities further, in case demand arises”, shared Rishad Dadachanji, director, Schott Kaisha.

In addition, all major pharma companies and many other players in the market have been processing the company’s vials on their fill and finish lines for many years. “Hence, no time-consuming adaptations of fill and finish equipment will slow down vaccine distribution. As time is a luxury the industry doesn’t have at the moment, it is common sense to rely on tried-and-true packaging solutions,” Dadachanji said.

Background information on Borosilicate glass

Schott is one of the world’s leading experts in the production of type-I Borosilicate glass, the gold standard for drug packaging for over a century. According to the company, the material is best suited for potential Covid-19 vaccines and existing medications, as it avoids the interactions between containers and the drug formulation, which can limit its effectiveness.

Headquartered in Mainz, Germany, Schott is a leading international technology group in specialty glass, glass-ceramics, and related high-tech materials. With over 130 years of experience, the company is an innovative partner to many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive, and aviation industries. Schott has a global presence with production sites and sales offices in 34 countries, including India.

Schott Kaisha was established in 1990 as a premium manufacturer of pharmaceutical containers made of neutral glass in India under the name Kaisha Manufacturers. In 2008, it started cooperation with the international technology group Schott. The Indo-German joint venture is a leading supplier for the pharmaceutical industry. It offers a “one-stop shop” solution for the entire range of small volume tubular glass parenteral packaging, including ampoules and vials cartridges, and sterile pre-fillable glass syringes.

The Covid-19 pandemic led to the country-wide lockdown on 25 March 2020. It will be two years tomorrow as I write this. What have we learned in this time? Maybe the meaning of resilience since small companies like us have had to rely on our resources and the forbearance of our employees as we have struggled to produce our trade platforms.

The print and packaging industries have been fortunate, although the commercial printing industry is still to recover. We have learned more about the digital transformation that affects commercial printing and packaging. Ultimately digital will help print grow in a country where we are still far behind in our paper and print consumption and where digital is a leapfrog technology that will only increase the demand for print in the foreseeable future.

Web analytics show that we now have readership in North America and Europe amongst the 90 countries where our five platforms reach. Our traffic which more than doubled in 2020, has at times gone up by another 50% in 2021. And advertising which had fallen to pieces in 2020 and 2021, has started its return since January 2022.

As the economy approaches real growth with unevenness and shortages a given, we are looking forward to the PrintPack India exhibition in Greater Noida. We are again appointed to produce the Show Daily on all five days of the show from 26 to 30 May 2022.

It is the right time to support our high-impact reporting and authoritative and technical information with some of the best correspondents in the industry. Readers can power Packaging South Asia’s balanced industry journalism and help sustain us by subscribing.

– Naresh Khanna

Subscribe Now

LEAVE A REPLY

Please enter your comment!
Please enter your name here